This study analyzed real-world outcomes in 225 patients with metastatic non-small cell lung cancer (NSCLC) and a high PD-L1 tumor proportion score (TPS ≥ 50%) who were treated with first-line pembrolizumab monotherapy between 2019 and 2022 in Serbia. This evidence concerns the gene CD274 and non-small cell lung carcinoma.